# US 2015/0177248 A1 · Use of sirt7 as novel cancer therapy target and method for treating cancer using the same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0177248 A1
- Document ID: US20150177248A1
- Status: Published application
- Kind: A1
- Application number: 14/138,035
- Filed: 2013-12-21
- Published: 2015-06-25
- Earliest claimed: 2013-12-21
- Assignees: Catholic University Industry Academic
- Applicants: Catholic University Industry Academic
- Inventors: Suk-Woo Nam; Jeong-Kyu Kim
- Web page: https://patentgrep.com/patent/US20150177248A1

## CPC

- G01N 33/57525: of the liver or pancreas
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/141: MicroRNAs, miRNAs
- C12N 2320/11: for the determination of target sites, i.e. of active nucleic acids
- C12Q 2600/158: Expression markers
- C12Y 305/01098: Histone deacetylase (3.5.1.98), i.e. sirtuin deacetylase
- G01N 2500/10: involving cells
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C12Y: ENZYMES

## Abstract

The present invention relates to the use of SIRT7 (sirtuin 7) as a marker for diagnosis of liver cancer. More specifically, the invention relates to a liver cancer diagnostic marker comprising SIRT7 gene, a liver cancer diagnostic composition, kit and microarray comprising the same, and a method of diagnosing liver cancer using the same. The invention also relates to a method for screening a substance capable of preventing or treating liver cancer by inhibiting the expression of SIRT7 gene or protein, and to a composition for preventing or treating liver cancer, which comprises the substance. The expression level of SIRT7 gene is higher in liver cancer tissue or cells than in non-liver cancer tissue or cells. Thus, when SIRT7 gene is used as a cancer diagnostic marker, cancer can be early diagnosed and predicted in a rapid and accurate manner, and it can be used as a target for development of an agent for preventing or treating cancer. Moreover, the invention is based on the finding that the expression of SIRT7 gene is indicative of the development and proliferation of cancer cells, and cell cycle transition, and thus the invention relates to the use of SIRT7 gene as a cancer diagnostic marker and to the anticancer use of inhibition of SIRT7 expression. In addition, the invention is based on the relationship between the SIRT7 expression and a specific miRNA, and thus relates to the use of the specific miRNA to regulate the cell cycle and inhibit tumor growth.

## Claims

### Claim 1

A cancer diagnostic marker comprising a substance for measuring the level of SIRT7 (sirtuin 7) gene or the level of SIRT7 protein.

### Claim 2 (depends on 1)

The cancer diagnostic marker of claim 1, wherein the SIRT7 gene has a nucleotide sequence of SEQ ID NO: 1.

### Claim 3 (depends on 1)

The cancer diagnostic marker of claim 1, wherein the substance for measuring the level of SIRT7 gene is a primer that can amplify the SIRT7 gene or a probe that can specifically bind to the SIRT7 gene.

### Claim 4 (depends on 1)

The cancer diagnostic marker of claim 1, wherein the substance for measuring the level of SIRT7 protein is an antibody or aptamer that specifically binds to the SIRT7 gene.

### Claim 5 (depends on 1)

The cancer diagnostic marker of claim 1, wherein the cancer is at least one cancer selected from the group consisting of hepatocellular carcinoma (HCC), biliary duct cancer, and metastatic liver cancer.

### Claim 6

A method of diagnosing or prognosing cancer, the method comprising the steps of: (a) measuring the expression level of the SIRT7 (sirtuin 7) gene or the level of the SIRT7 protein in a biological sample; and
(b) comparing the results measured in step (a) with the expression level of the SIRT7 (sirtuin 7) gene or the level of the SIRT7 protein in a normal control sample.

### Claim 7 (depends on 6)

The method of claim 6, wherein the biological sample is at least one selected the group consisting of tissues, cells, whole blood, serum, plasma, saliva, and urine.

### Claim 8 (depends on 6)

The method of claim 6, wherein the cancer is at least one cancer selected from the group consisting of hepatocellular carcinoma (HCC), biliary duct cancer, and metastatic liver cancer.

### Claim 9 (depends on 6)

The method of claim 6, wherein the measurement of the expression level of the SIRT7 gene or the level of the SIRT7 protein is performed by any one selected from the group consisting of reverse transcriptase-polymerase chain reaction, real-time polymerase chain reaction, Western blotting, Northern blotting, ELISA (enzyme linked immunosorbent assay), RIA (radioimmunoassay), radioimmunodiffusion, and immunoprecipitation assay.

### Claim 10

A method for preventing or treating cancer by administration of a composition comprising, as an active ingredient, an antisense or siRNA (small interference RNA) oligonucleotide having a sequence complementary to a nucleotide sequence of the SIRT7 (sirtuin 7) gene.

### Claim 11 (depends on 10)

The method of claim 10, wherein the siRNA oligonucleotide has a nucleotide sequence set forth in SEQ ID NO: 3 or 4.

### Claim 12 (depends on 10)

The method of claim 10, wherein the cancer is at least one cancer selected from the group consisting of hepatocellular carcinoma (HCC), biliary duct cancer, and metastatic liver cancer.

### Claim 13

A method of diagnosing or prognosing SIRT7-expressing cancer by examining the expression profiling of miR-125a-5p or miR-125b.

### Claim 14 (depends on 13)

The method of claim 13, wherein the SIRT7-expressing cancer is at least one liver cancer selected from the group consisting of hepatocellular carcinoma (HCC), biliary duct cancer, and metastatic liver cancer.

### Claim 15

A method for treating SIRT7-expressing cancer by administering an anticancer composition against the cancer, wherein the anticancer composition comprises, as an active ingredient, an agent for promoting the expression or activity of miR-125a-5p or miR-125b.

### Claim 16 (depends on 15)

The method of claim 15, wherein the SIRT7-expressing cancer is at least one liver cancer selected from the group consisting of hepatocellular carcinoma (HCC), biliary duct cancer, and metastatic liver cancer.

### Claim 17 (depends on 15)

The method of claim 15, wherein THE miR-125a-5p has a nucleotide sequence set forth in SEQ ID NO: 7 and the miR-125b has a nucleotide sequence set forth in SEQ ID NO: 8.

### Claim 18 (depends on 15)

The method of claim 15, wherein the agent for promoting the expression or activity of miR-125a-5p or miR-125b is a vector encoding miR-125a-5p or miR-125b, a hypermethylation inhibitor, or a p53 activator.

### Claim 19 (depends on 15)

The method of claim 15, wherein the anticancer composition transfects SIRT7-expressing cancer cells so as to cause miR-125a-5p or miR-125b to bind to SIRT7 mRNA 3′UTR to thereby inhibit the expression of SIRT7.

### Claim 20 (depends on 15)

The method of claim 15, wherein the anticancer composition comprises a cationic lipid or cationic amphipathic substance.

### Claim 21 (depends on 16)

The method of claim 16, wherein the anticancer composition arrests the cell cycle at G1/S phase.

### Claim 22

A method of treating cancer by regulating the expression of SIRT7 gene using a miRNA selected from miR-125a-5p and miR-125b, the method comprising: either a step of bringing SIRT7 into contact with said miRNA, or a step of bringing SIRT7 into contact with a vector encoding miR-125a-5p that targets the SIRT7 gene.

### Claim 23 (depends on 22)

The method of claim 22, wherein the expression of the SIRT7 gene inhibited by overexpressing or activating the miR-125a-5p or miR-125b.

### Claim 24 (depends on 22)

The method of claim 22, wherein the overexpressing or activating of the miR-125a-5p or miR-125b is achieved by inhibiting promoter methylation or inducing p53 activation.

### Claim 25

A method for screening a substance for treating liver cancer, the method comprising the steps of:
(a) treating an animal cell, which expresses miR-125a-5p or miR-125b, with an anticancer candidate substance; and
(b) selecting the candidate substance as a substance for treating liver cancer when the expression of miR-125a-5p or miR-125b in the animal cell is increased compared to a control group not treated with the candidate substance.

### Claim 26 (depends on 25)

The method of claim 25, wherein the cancer is at least one cancer selected from the group consisting of hepatocellular carcinoma (HCC), biliary duct cancer, and metastatic liver cancer.

### Claim 27 (depends on 25)

The method of claim 25, wherein the animal cell expressing the miR-125a-5p or miR-125b is at least one liver cancer cell selected from the group consisting of hepatocellular carcinoma (HCC), biliary duct cancer, and metastatic liver cancer.
